ES2148179T3 - Compuesto de 4-amino(alquil)ciclohexan-1-carboxamida y uso del mismo. - Google Patents
Compuesto de 4-amino(alquil)ciclohexan-1-carboxamida y uso del mismo.Info
- Publication number
- ES2148179T3 ES2148179T3 ES92918882T ES92918882T ES2148179T3 ES 2148179 T3 ES2148179 T3 ES 2148179T3 ES 92918882 T ES92918882 T ES 92918882T ES 92918882 T ES92918882 T ES 92918882T ES 2148179 T3 ES2148179 T3 ES 2148179T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- coronary
- cerebral
- renal
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
UN COMPUESTO 4 DA REPRESENTADO POR LA FORMULA GENERAL (I), UN ISOMERO CONSIGUIENTE Y UNA ACIDO MAS SAL ACEPTABLE FARMACEUTICAMENTE, DONDE CADA SIMBOLO ES COMO SE DEFINE EN LA ESPECIFICACION. ESTAS SUSTANCIAS CON UNA RESEÑABLE ACTIVIDAD ALTAMENTE PERSISTENTE Y DE BAJA TOXICIDAD PARA AUMENTAR EL FLUJO SANGUINEO EN ARTERIAS CORONARIAS, CEREBRALES, RENALES Y PERIFERICAS, Y SON UTILES COMO UN POTENTE Y PERSISTENTE HIPOTENSOR Y MEDICAMENTO PARA EVITAR Y TRATAR ENFERMEDADES DE UN SISTEMA CARDIOVASCULAR TAL COMO ARTERIAS CORONARIAS, CEREBRALES, RENALES Y PERIFERICAS. ADEMAS, SON UTILES COMO ANTIASMATICO DADO QUE TIENE ACTIVIDADES DE INHIBICION DEL ASMA DEL COCHINILLO DE INDIAS EXPERIMENTAL CAUSADA POR LA INHALACION DE HISTAMINA Y CONTRACCION INHIBIDORA DE UN ESPECIMEN DE TRAQUEA EXTIRPADA A UN COCHINILLO DE INDIAS OCASIONADA POR ACETILCOLINA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25568991 | 1991-09-06 | ||
JP14617592 | 1992-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2148179T3 true ES2148179T3 (es) | 2000-10-16 |
Family
ID=26477067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92918882T Expired - Lifetime ES2148179T3 (es) | 1991-09-06 | 1992-09-04 | Compuesto de 4-amino(alquil)ciclohexan-1-carboxamida y uso del mismo. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5478838A (es) |
EP (1) | EP0641781B1 (es) |
KR (2) | KR0133372B1 (es) |
AT (1) | ATE194977T1 (es) |
CA (1) | CA2117096C (es) |
DE (1) | DE69231297T2 (es) |
DK (1) | DK0641781T3 (es) |
ES (1) | ES2148179T3 (es) |
GR (1) | GR3034633T3 (es) |
WO (1) | WO1993005021A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
EP0714898B1 (en) * | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
ATE359822T1 (de) | 1996-08-12 | 2007-05-15 | Mitsubishi Pharma Corp | Medikamente enthaltend rho-kinase inhibitoren |
DE19652374A1 (de) * | 1996-12-04 | 1998-06-10 | Schering Ag | Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
ES2247822T3 (es) * | 1998-08-17 | 2006-03-01 | Senju Pharmaceutical Co., Ltd. | Medicamentos preventivos/curativos para glaucoma. |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
JP4776138B2 (ja) * | 2000-03-31 | 2011-09-21 | 田辺三菱製薬株式会社 | 腎臓疾患予防・治療剤 |
US20020177207A1 (en) * | 2001-03-14 | 2002-11-28 | Myriad Genetics, Incorporated | Tsg101-interacting proteins and use thereof |
WO2002083175A1 (fr) * | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Agents ameliorant la fonction visuelle |
BR0309475A (pt) * | 2002-04-23 | 2005-03-01 | Shionogi & Co | Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmos |
US20040028716A1 (en) * | 2002-06-14 | 2004-02-12 | Marks Andrew R. | Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation |
CA2400996A1 (en) * | 2002-09-03 | 2004-03-03 | Lisa Mckerracher | 1,4-substituted cyclohexane derivatives |
US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
WO2005019221A1 (en) * | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
GB0403635D0 (en) * | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
WO2005080394A1 (en) * | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
JP5071374B2 (ja) * | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
WO2008049000A2 (en) * | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
US20100105661A1 (en) * | 2007-01-12 | 2010-04-29 | Astellas Pharma Inc. | Condensed pyridine compound |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
ES2849181T3 (es) | 2009-04-22 | 2021-08-16 | Viacyte Inc | Composiciones celulares derivadas de células reprogramadas desdiferenciadas |
ES2938049T3 (es) | 2009-10-16 | 2023-04-04 | Scripps Research Inst | Inducción de células pluripotentes |
JP5902092B2 (ja) | 2009-10-19 | 2016-04-13 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 心筋細胞の生成 |
KR101861168B1 (ko) | 2010-06-15 | 2018-05-31 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 작은 부피의 말초 혈액으로부터의 유도된 만능 줄기 세포의 생성 |
JP6182456B2 (ja) | 2010-12-22 | 2017-08-23 | フェイト セラピューティクス,インコーポレイテッド | 単細胞選別のための細胞培養プラットホームおよびiPSCの再プログラミングの増強 |
US20130040302A1 (en) | 2011-07-11 | 2013-02-14 | Thomas J. Burke | Methods for cell reprogramming and genome engineering |
TW201416362A (zh) | 2012-07-19 | 2014-05-01 | Dainippon Sumitomo Pharma Co | 1-(環烷基羰基)脯胺酸衍生物 |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
CN105358680B (zh) | 2013-04-03 | 2019-06-25 | 富士费勒姆细胞动力学有限公司 | 用于悬浮培养内胚层祖细胞的方法和组合物 |
EP3604499A1 (en) | 2014-03-04 | 2020-02-05 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
TW202344686A (zh) | 2015-10-30 | 2023-11-16 | 美國加利福尼亞大學董事會 | 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法 |
US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
US10537567B2 (en) | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
UY38427A (es) | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
WO2021138331A2 (en) * | 2019-12-30 | 2021-07-08 | Memorial Sloan Kettering Cancer Center | Small molecule inhibitors of ulk1 |
US20230348852A1 (en) | 2020-04-27 | 2023-11-02 | Novartis Ag | Methods and compositions for ocular cell therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6456661A (en) * | 1987-05-29 | 1989-03-03 | Yoshitomi Pharmaceutical | Amino pyridine derivative |
JP2770497B2 (ja) * | 1988-11-24 | 1998-07-02 | 吉富製薬株式会社 | トランス―4―アミノ(アルキル)―1―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 |
WO1990005723A1 (en) * | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use |
-
1992
- 1992-09-04 KR KR1019940700738A patent/KR0133372B1/ko active
- 1992-09-04 KR KR1019940700738A patent/KR940702451A/ko not_active IP Right Cessation
- 1992-09-04 ES ES92918882T patent/ES2148179T3/es not_active Expired - Lifetime
- 1992-09-04 AT AT92918882T patent/ATE194977T1/de active
- 1992-09-04 CA CA002117096A patent/CA2117096C/en not_active Expired - Lifetime
- 1992-09-04 US US08/204,211 patent/US5478838A/en not_active Expired - Lifetime
- 1992-09-04 EP EP92918882A patent/EP0641781B1/en not_active Expired - Lifetime
- 1992-09-04 DE DE69231297T patent/DE69231297T2/de not_active Expired - Lifetime
- 1992-09-04 DK DK92918882T patent/DK0641781T3/da active
- 1992-09-04 WO PCT/JP1992/001139 patent/WO1993005021A1/ja active IP Right Grant
-
2000
- 2000-10-16 GR GR20000402319T patent/GR3034633T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2117096A1 (en) | 1993-03-18 |
DK0641781T3 (da) | 2000-09-18 |
ATE194977T1 (de) | 2000-08-15 |
EP0641781A4 (en) | 1994-12-16 |
WO1993005021A1 (en) | 1993-03-18 |
EP0641781A1 (en) | 1995-03-08 |
CA2117096C (en) | 1997-11-04 |
US5478838A (en) | 1995-12-26 |
DE69231297D1 (de) | 2000-08-31 |
KR940702451A (ko) | 1994-08-20 |
KR0133372B1 (ko) | 1998-04-23 |
DE69231297T2 (de) | 2000-11-23 |
EP0641781B1 (en) | 2000-07-26 |
GR3034633T3 (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2148179T3 (es) | Compuesto de 4-amino(alquil)ciclohexan-1-carboxamida y uso del mismo. | |
ATE164575T1 (de) | Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer | |
BR9713552A (pt) | Derivados de pirimidina bicìclicos condensados | |
DE69705829D1 (de) | Meta-substituierte phenylsulphonamidderivate | |
DE69033915D1 (de) | Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung | |
NO932442D0 (no) | Anvendelse av 1,3-oksatiolannukleosidanaloger ved behandling av hepatitt b | |
CA2335285A1 (en) | Bicyclic piperidine and piperazine compounds having 5-ht6 receptor affinity | |
HUT68856A (en) | Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions | |
DE122011100040I2 (de) | Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren. | |
NO306992B1 (no) | Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene | |
CA2238875A1 (en) | Tri-aryl ethane derivatives as pde iv inhibitors | |
DK0665834T3 (da) | Quinolon- og acridinonderivater til behandling af urininkontinens | |
FI940229A (fi) | Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö | |
DE60045033D1 (de) | Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung | |
ATE48001T1 (de) | Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate. | |
ES2128355T3 (es) | Nuevo derivado bisheterociclico o su sal y composicion hipoglicemica. | |
EP0206616A3 (en) | Quinolones having antihypertensive activity | |
KR900016227A (ko) | 이소티아졸로피리돈의 아제티딘 유도체, 그의 제조방법 및 의약품으로의 응용 | |
ES2111086T3 (es) | Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos. | |
DE69300318D1 (de) | Flavonderivate. | |
EP0525203A4 (en) | Substituted sulfonamide derivative or pharmaceutical composition containing the same | |
DK1264836T3 (da) | Fremgangsmåde til fremstilling af indolopyrrolocarbaxolderivater | |
FR2823749B1 (fr) | Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
DE69021518D1 (de) | 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-5-nitropyridin-3-carbonsäure-1-azabicyclo[2.2.2]oct-3-ylester-Isomere. | |
NO951966L (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 641781 Country of ref document: ES |